p27 and p21 in gene therapies
    33.
    发明授权
    p27 and p21 in gene therapies 有权
    p27和p21基因治疗

    公开(公告)号:US07462483B2

    公开(公告)日:2008-12-09

    申请号:US09803687

    申请日:2001-03-09

    IPC分类号: C12N5/08

    摘要: The expansion of a population of stem cells or progenitor cells, or precursors thereof, may be accomplished by disrupting or inhibiting p21cip1/waf1 and/or p27, cyclin dependent kinase inhibitors. In the absence of p27 activity, progenitor cells move into the cell cycle and proliferate; whereas in the absence of p21 activity, stem cells move into the cell cycle and proliferate without losing their pluripotentiality (i.e., their ability to differentiate into the various cell lines found in the blood stream). Any type of stem cell or progenitor cell, or precursor thereof, including, but not limited to, hematopoietic, gastrointestinal, lung, neural, skin, muscle, cardiac muscle, renal, mesenchymal, embryonic, fetal, or liver cell may be used in accordance with the invention. The present invention provides a method of expanding a cell population, cells with decreased p27 and/or p21 activity, transgenic animals with a disrupted p27 and/or p21 gene, pharmaceutical compositions comprising the cells of the invention, and methods of using these cells in gene therapy (e.g., stem cell gene therapy) and bone marrow transplantation.

    摘要翻译: 干细胞或祖细胞群或其前体的扩增可以通过破坏或抑制p21cip1 / waf1和/或p27细胞周期蛋白依赖性激酶抑制剂来实现。 在没有p27活性的情况下,祖细胞进入细胞周期并增殖; 而在没有p21活性的情况下,干细胞进入细胞周期并增殖而不丧失其多能性(即,它们分化成血液中发现的各种细胞系的能力)。 包括但不限于造血,胃肠,肺,神经,皮肤,肌肉,心肌,肾,间充质,胚胎,胎儿或肝细胞的任何类型的干细胞或祖细胞或其前体可用于 根据本发明。 本发明提供了扩增细胞群的方法,具有降低的p27和/或p21活性的细胞,具有破坏的p27和/或p21基因的转基因动物,包含本发明细胞的药物组合物,以及使用这些细胞的方法 基因治疗(如干细胞基因治疗)和骨髓移植。

    Method of screening a compound for hematopoietic activity
    35.
    发明授权
    Method of screening a compound for hematopoietic activity 失效
    筛选化合物造血活性的方法

    公开(公告)号:US5965437A

    公开(公告)日:1999-10-12

    申请号:US107737

    申请日:1998-06-30

    申请人: David T. Scadden

    发明人: David T. Scadden

    摘要: Methods of selecting a population of human cells containing quiescent pluripotent hematopoietic progenitor cells substantially free of mature, human myeloid and lymphoid cells, the quiescent pluripotent progenitor cells obtained by these methods, and methods of using the pluripotent progenitor cells are described.

    摘要翻译: 描述了选择含有基本上不含成熟的人类骨髓和淋巴细胞的静止多能造血祖细胞的人类细胞群,通过这些方法获得的静止多能祖细胞的方法和使用多能祖细胞的方法。